The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.
 
Matteo Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Innovent Biologics; Medison; Medison; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi; Strand Therapeutics
 
Adnan Khattak
Honoraria - Evaxion Biotech
Consulting or Advisory Role - Moderna Therapeutics
Travel, Accommodations, Expenses - Evaxion Biotech; Moderna Therapeutics; Pierre Fabre
 
Tarek Meniawy
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; MSD; Novartis; Regeneron; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - BMS Brazil; Eisai
 
George Ansstas
Consulting or Advisory Role - Immunocore; Regeneron
 
Matthew Taylor
Honoraria - Bristol Myers Squibb Foundation; Exelixis
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Kevin Kim
Stock and Other Ownership Interests - Arvinas; crispr therapeutics; Cryoport; Vertex
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Jazz Pharmaceuticals; Merck; Merck; Novartis; Pfizer; Sanofi/Regeneron; Sanofi/Regeneron
Speakers' Bureau - Bristol Myers Squibb Foundation; Sanofi/Regeneron
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Regeneron (Inst); SpringWorks Therapeutics; Summit pharmaceuticals (Inst)
 
Meredith McKean
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Daiichi Sankyo (Inst); IDEAYA Biosciences (Inst); IQvia (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Regeneron (Inst); Revolution Medicines (Inst)
Research Funding - Arcus Biosciences (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GenVivo (Inst); Gilead Sciences (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); immatics (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Jazz Pharmaceuticals (Inst); Kezar Life Sciences (Inst); Krystal Biotech (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nested Therapeutics (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Pfizer (Inst); Pierre Fabre (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Repimune (Inst); Sapience Therapeutics (Inst); Synthorx (Inst); Teva (Inst); TScan Therapeutics (Inst)
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; AstraZeneca; AstraZeneca/UK; Aulos Bioscience; Bayer; BioNTech SE; Boehringer Ingelheim; Bristol Myers Squibb; Byondis; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics; Strand Therapeutics
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; PharmaMar; Replimune
Research Funding - BeiGene (Inst); BioMed Valley Discoveries (Inst); BioNTech SE (Inst); Compugen (Inst); Georgimmune (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Synthekine (Inst)
 
Mark Faries
Consulting or Advisory Role - Merck; Novartis; Regeneron; Replimune
 
Thuy Tran
No Relationships to Disclose
 
Charles Cowey
Employment - Texas Oncology; US Oncology
Leadership - US Oncology
Consulting or Advisory Role - Replimune
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst)
 
Andrew Pecora
Employment - Celularity Inc; Cota Healthcare; Outcomes Matter Innovations (OMI); Regional Cancer Care Associates
Leadership - Celularity Inc; Cota Healthcare; Genetic testing cooperative (GTC); Regional Cancer Care Associates
Stock and Other Ownership Interests - Celularity Inc; Cota Healthcare; Genetic testing cooperative (GTC); Regional Cancer Care Associates
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Cd34 patents COTA patents
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Theresa Medina
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Day One Biopharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Merck/Eisai (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Ultimovacs (Inst)
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Immtech; Immunocore; Merck Sharp & Dohme; Novartis; Pierre Fabre; Primmune Therapeutics; Provectus Biopharmaceuticals; QBiotics
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; QBiotics
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Expert Testimony - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; OncoSec; Pierre Fabre
 
Clemens Krepler
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Thomas Jemielita
Employment - Merck Sharp & Dohme
 
Huzhang Mao
Stock and Other Ownership Interests - Lilly; Moderna Therapeutics
 
Mariana Faria-Urbina
Employment - Moderna Therapeutics
 
Janice Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - HMP; Medscape
Consulting or Advisory Role - Bristol-Myers Squibb; Cugene; Immunocore; Merck Sharp & Dohme; Moderna Therapeutics; Sanofi/Regeneron; Sun Pharma
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); Deciphera (Inst); GV20 Therapeutics; Incyte (Inst); Kinnate Biopharma (Inst); Merck (Inst); Nested Therapeutics; Novartis (Inst); Regeneron (Inst)